Skip to main content
NRXP
NASDAQ Life Sciences

NRX Pharmaceuticals Reports Going Concern, Massive Dilution, and Key Regulatory Progress in Annual 10-K

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.77
Mkt Cap
$56.414M
52W Low
$1.58
52W High
$3.84
52W Position info
12% above low
Off High info
54% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

NRXP is trading near its 52-week low of $1.58 (12% above the low).

Summary

NRX Pharmaceuticals' 2025 10-K reveals a 'going concern' warning and a 126% increase in shares outstanding due to dilutive financing, alongside significant regulatory progress for its key drug candidates and initial revenue from its new subsidiary.


Key Events · Financing and Capital Events · NRXP

  • Going Concern Warning Issued

    The company's financial statements include a 'going concern' warning, indicating substantial doubt about its ability to continue operations for at least the next 12 months due to recurring losses and negative cash flows.

  • Significant Dilutive Financing Activities in 2025

    NRX Pharmaceuticals raised $23.3 million in cash through various financing activities in 2025, including an At-The-Market (ATM) offering, conversion of $16.3 million in Anson Notes into common stock, a Registered Direct Offering, and warrant exercises. These activities led to a 126.6% increase in shares outstanding from December 31, 2024, to December 31, 2025.

  • Positive Regulatory Milestones Achieved

    The company received a preliminary FDA determination of no bioequivalence deficiency for KETAFREE™ (generic ketamine) in March 2026, with commercial sales anticipated in Q3 2026. Additionally, the FDA agreed to review existing clinical trials and Real World Evidence for the NRX-100 NDA, expected in Q2 2026.

  • HOPE Therapeutics Subsidiary Begins Generating Revenue

    The HOPE Therapeutics subsidiary, focused on interventional psychiatry care, became revenue-generating in Q4 2025 through the acquisition of Dura Medical, LLC, and is actively expanding its clinical footprint and leadership team.


Analysis · NRXP · Life Sciences

NRX Pharmaceuticals' 2025 annual report highlights a critical 'going concern' warning, indicating substantial doubt about its ability to continue operations for the next 12 months. This financial distress is underscored by a significant net loss and increased cash burn. To address these challenges, the company undertook highly dilutive financing activities in 2025, raising $23.3 million but increasing outstanding shares by over 126%. Despite the severe financial headwinds, the company reported notable progress in its drug development pipeline, including a preliminary FDA determination for KETAFREE™ and FDA agreement on Real World Evidence for NRX-100, both targeting multi-billion dollar markets. The launch of its HOPE Therapeutics subsidiary also generated initial revenue. This filing presents a high-stakes scenario where aggressive, dilutive capital raises are critical for survival, while pipeline advancements offer potential long-term value.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NRXP was trading at $1.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56.4M. The 52-week trading range was $1.58 to $3.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NRXP - Latest Insights

NRXP
Nov 17, 2026, 7:18 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.10
Real-time Price: $2.71 info
Change: +$0.610 (+29%) info
Market Cap: $120.794M info
NRXP
Oct 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.98
Real-time Price: $2.71 info
Change: -$0.2698 (-9%) info
Market Cap: $120.794M info
NRXP
Oct 15, 2026, 8:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.55
Real-time Price: $2.71 info
Change: +$0.160 (+6%) info
Market Cap: $120.794M info
NRXP
Oct 05, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.86
Real-time Price: $2.71 info
Change: -$0.150 (-5%) info
Market Cap: $120.794M info
NRXP
Sep 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.98
Real-time Price: $2.71 info
Change: -$0.2745 (-9%) info
Market Cap: $120.794M info